Ran HH, Zhang R, Lu XC, Yang B, Fan H, Zhu HL (2012) Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review. Journal of geriatric cardiology: JGC 9(4):411–414

PubMed  PubMed Central  Google Scholar 

Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C (2008) Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica 93(2):317–318

Article  PubMed  Google Scholar 

Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E (2010) Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res 34(6):827–829

Article  CAS  PubMed  Google Scholar 

Kekäle M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733–1740

Article  PubMed  PubMed Central  Google Scholar 

Adenis A, Bouché O, Bertucci F, Kalbacher E, Fournier C, Cassier P et al (2012) Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. Medical oncology (Northwood, London, England) 29(4):3003–3008

Article  CAS  PubMed  Google Scholar 

Penel N, Blay JY, Adenis A (2008) Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 358(25):2746–2747

Article  CAS  PubMed  Google Scholar 

Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908–916

Article  PubMed  Google Scholar 

Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E (2007) In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.’ Nature med 13(1):13–14. author reply 5–6

Article  PubMed  Google Scholar 

Hatfield A, Owen S, Pilot PR (2007) In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.’ Nature med 13(1):13. author reply 5–6

Article  CAS  PubMed  Google Scholar 

Saad SY, Alkharfy KM, Arafah MM (2006) Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol 58(4):567–573

Article  CAS  PubMed  Google Scholar 

Dong B, Chen DF, Bu XH, Qin HB, Xi Y (2020) Effect of imatinib on DOCA-induced myocardial fibrosis in rats through P38 MAPK signaling pathway. Eur Rev Med Pharmacol Sci 24(4):2028–2036

CAS  PubMed  Google Scholar 

Al-Ali HK, Krahl R, Orth M, Perlowski S, Otto S, Deininger MW et al (2004) Persistently increased creatine kinase levels in patients with chronic myeloid leukemia treated with imatinib correlate with major cytogenetic remission. Blood 104(11):2933

Article  Google Scholar 

Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879–894

Article  CAS  PubMed  Google Scholar 

Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clinical cancer research: an official journal of the American Association for Cancer Research 17(3):406–415

Article  CAS  PubMed  Google Scholar 

Mlejnek P, Dolezel P, Faber E, Kosztyu P (2011) Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol 90(7):837–842

Article  CAS  PubMed  Google Scholar 

Filppula AM, Laitila J, Neuvonen PJ, Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165(8):2787–2798

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291–299

Article  Google Scholar 

Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022–4028

Article  CAS  PubMed  Google Scholar 

Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496–3499

Article  CAS  PubMed  Google Scholar 

Bankar A, Lipton JH (2022) Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study. Leuk Lymphoma 63(1):179–188

Article  CAS  PubMed  Google Scholar 

Nasser A, Hussein A, Chamba C, Yonazi M, Mushi R, Schuh A et al (2021) Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania. Blood Adv 5(5):1403–1411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jabbour E, Jones D, Kantarjian HM, O’Brien S, Tam C, Koller C et al (2009) Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037–2043

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30(1):48–56

Article  CAS  PubMed  Google Scholar 

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63(4):789–799

Article  CAS  PubMed  Google Scholar 

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute 90(11):850–8

Article  CAS  PubMed  Google Scholar 

Hewitt J, Rusnak D, Cox-Kennett N, Larratt L, Turner R (2007) HyperCKemia in CML patients on imatinib mesylate. Blood 110:2965

Article  Google Scholar 

Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884

Article  CAS  PubMed  PubMed Central  Google Scholar 

Omran MM, Abdelfattah R, Moussa HS, Alieldin N, Shouman SA (2020) Association of the trough, peak/trough ratio of imatinib, pyridine-N-oxide imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G with imatinib response in Egyptian chronic myeloid leukemia patients. Front Oncol 10:1348

Article  PubMed  PubMed Central  Google Scholar 

Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P et al (2005) Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 27(5):634–640

Article  CAS  PubMed  Google Scholar 

Shimazaki C, Ochiai N, Uchida R, Fuchida SI, Okano A, Ashihara E et al (2003) Intramuscular edema as a complication of treatment with imatinib. Leukemia 17(4):804–805

Article  CAS  PubMed  Google Scholar 

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research 8(5):935–942

CAS  PubMed  Google Scholar 

Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354(19):2006–2013

Article  CAS  PubMed  Google Scholar 

Betsholtz C (2003) Biology of platelet-derived growth factors in development. Birth Defects Res C Embryo Today 69(4):272–285

Article  CAS  PubMed  Google Scholar 

Zhao Y, Haginoya K, Sun G, Dai H, Onuma A, Iinuma K (2003) Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J Pathol 201(1):149–159

Article  CAS  PubMed  Google Scholar 

Baird MF, Graham SM, Baker JS, Bickerstaff GF (2012) Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. Journal of nutrition and metabolism 2012:960363

Article  PubMed  PubMed Central  Google Scholar 

Oosthuyse T, Bosch AN (2017) The effect of gender and menstrual phase on serum creatine kinase activity and muscle soreness following downhill running. Antioxidants (Basel, Switzerland). 6(1)

Cook JC, Wong E, Haywood LJ (1990) Creatine kinase: race-gender differences in patients hospitalized for suspected myocardial infarction. J Natl Med Assoc 82(4):249–254

CAS  PubMed